Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;1(3):10.1056/evidoa2100028.
doi: 10.1056/evidoa2100028. Epub 2022 Feb 3.

Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management

James R O'Dell  1   2 , Mary T Brophy  3   4 , Michael H Pillinger  5   6 , Tuhina Neogi  7 , Paul M Palevsky  8   9 , Hongsheng Wu  3   10 , Anne Davis-Karim  11 , Jeff A Newcomb  1   2 , Ryan Ferguson  3 , David Pittman  11 , Grant W Cannon  12 , Thomas Taylor  13   14 , Robert Terkeltaub  15 , Amy C Cannella  1   2 , Bryant R England  1   2 , Lindsay N Helget  1   2 , Ted R Mikuls  1   2
Affiliations

Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management

James R O'Dell et al. NEJM Evid. 2022 Mar.

Erratum in

Abstract

Background: The relative efficacy and safety of allopurinol and febuxostat when used according to current guidelines for the treatment of hyperuricemia are unknown. This double-blind noninferiority trial examined these issues.

Methods: Participants with gout and hyperuricemia (with at least 33% having stage 3 chronic kidney disease) were randomly assigned to allopurinol or febuxostat in this 72-week trial, with doses titrated to target serum urate. The trial had three phases: titration (weeks 0 to 24), maintenance (weeks 25 to 48), and observation (weeks 49 to 72). Allopurinol and febuxostat were initiated at daily doses of 100 and 40 mg, with maximum titration to 800 and 120 mg, respectively. Antiinflammatory prophylaxis was given during phases 1 and 2. The primary end point was the proportion of patients experiencing one or more flares during phase 3, with a prespecified noninferiority margin of less than 8 percentage points between allopurinol and febuxostat. Secondary end points included efficacy in patients with chronic kidney disease, proportion achieving target serum urate levels, and serious adverse events.

Results: This study included 940 participants; 20.1% withdrew, with similar proportions in treatment arms. During phase 3, 36.5% of allopurinol-treated participants had one flare or more compared with 43.5% of febuxostat-treated participants (P<0.001 for noninferiority). Overall, 80% of participants achieved mean target urates during phase 2 with no differences by treatment. There were no treatment differences (including cardiovascular events) in serious adverse events.

Conclusions: Allopurinol and febuxostat achieved serum urate goals in patients with gout; allopurinol was noninferior to febuxostat in controlling flares. Similar outcomes were noted in participants with stage 3 chronic kidney disease. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; ClinicalTrials.gov identifier, NCT02579096.).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT Flow Diagram. CONSORT denotes Consolidated Standards of Reporting Trials.
See this image and copyright information in PMC

References

    1. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol 2019;71:991–9 10.1002/art.40807. - DOI - PMC - PubMed
    1. Elfishawi MM, Zleik N, Kvrgic Z, et al. The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol 2018;45:574–9 10.3899/jrheum.170806. - DOI - PMC - PubMed
    1. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57:109–15 10.1002/art.22466. - DOI - PubMed
    1. Krishnan E Reduced glomerular function and prevalence of gout: NHANES 2009–10. PLoS One 2012;7:e50046 10.1371/journal.pone.0050046. - DOI - PMC - PubMed
    1. Clarson LE, Chandratre P, Hider SL, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 2015;22:335–43 10.1177/2047487313514895. - DOI - PMC - PubMed

Associated data

LinkOut - more resources